379 related articles for article (PubMed ID: 35688560)
1. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
2. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.
Attrill GH; Lee H; Tasker AT; Adegoke NA; Ferguson AL; da Silva IP; Saw RPM; Thompson JF; Palendira U; Long GV; Ferguson PM; Scolyer RA; Wilmott JS
Front Immunol; 2022; 13():979993. PubMed ID: 36003398
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
4. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J; Del Vecchio M; Mandalá M; Gogas H; Arance Fernandez AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; Lutzky J; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill AG; Fecher LA; Millward M; Nathan PD; Khushalani NI; Queirolo P; Ritchings C; Lobo M; Askelson M; Tang H; Dolfi S; Ascierto PA; Weber J
Clin Cancer Res; 2023 Sep; 29(17):3352-3361. PubMed ID: 37058595
[TBL] [Abstract][Full Text] [Related]
6. Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy.
Shen YC; Yeh CP; Jeng YM; Hsu C; Hsu CH; Lin ZZ; Shao YY; Lu LC; Liu TH; Chen CH; Cheng AL
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680292
[TBL] [Abstract][Full Text] [Related]
7. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
8. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract][Full Text] [Related]
11. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
[TBL] [Abstract][Full Text] [Related]
12. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
Bhave P; Hong A; Lo SN; Johnson R; Mangana J; Johnson DB; Dulgar O; Eroglu Z; Yeoh HL; Haydon A; Lodde GC; Livingstone E; Khattak A; Kähler K; Hausschild A; McArthur GA; Menzies AM; Long G; Wang W; Carlino MS
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889810
[TBL] [Abstract][Full Text] [Related]
14. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
Coen O; Corrie P; Marshall H; Plummer R; Ottensmeier C; Hook J; Bell S; Sagoo GS; Meads D; Bestall J; Velikova G; Gallagher FA; Smith A; Howard H; Mason E; Katona E; Silva S; Collinson M; Rodwell S; Danson S
BMC Cancer; 2021 Jul; 21(1):761. PubMed ID: 34210290
[TBL] [Abstract][Full Text] [Related]
15. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.
Adegoke NA; Gide TN; Mao Y; Quek C; Patrick E; Carlino MS; Lo SN; Menzies AM; Pires da Silva I; Vergara IA; Long G; Scolyer RA; Wilmott JS
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865395
[TBL] [Abstract][Full Text] [Related]
16. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CD39
Yeong J; Suteja L; Simoni Y; Lau KW; Tan AC; Li HH; Lim S; Loh JH; Wee FYT; Nerurkar SN; Takano A; Tan EH; Lim TKH; Newell EW; Tan DSW
J Thorac Oncol; 2021 Aug; 16(8):1349-1358. PubMed ID: 33975004
[TBL] [Abstract][Full Text] [Related]
18. Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management.
Plunkett KR; Armitage JD; Inderjeeth AJ; McDonnell AM; Waithman J; Lau PKH
Front Immunol; 2022; 13():1048758. PubMed ID: 36466880
[TBL] [Abstract][Full Text] [Related]
19. Spatial features of specific CD103
Yang G; Cai S; Hu M; Li C; Yang L; Zhang W; Sun J; Sun F; Xing L; Sun X
J Transl Med; 2024 Jan; 22(1):27. PubMed ID: 38183111
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]